-
The GOP-led panel wrapped up a two-year investigation with criticism for lockdowns, vaccines, social distancing and masking mandates.
-
Respiratory viruses like COVID-19 spread more effectively in colder temperatures, putting younger children and older adults at greater risk for infection.
-
Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but not full protection against germs spreading in fall and winter. Infectious disease experts recommend what shots to get now.
-
The federal government is offering for the first time this year four, free COVID-19 testing kits. Experts say it's a move that highlights expectations of another busy respiratory infection season.
-
There's a new bulletin from Florida's surgeon general. Vaccine experts and historians interviewed for this article can’t remember another state health leader urging residents to avoid an FDA-approved vaccine.
-
Florida's health officials say COVID booster targets wrong strain. An expert says it will still workThe state agency advises people to skip the shot because it doesn’t target the current dominant variant. A USF epidemiologist says it will still be effective but suggests first asking whether you need the booster.
-
Although public health officials recommend the newly approved COVID vaccine for everyone age 6 months and older, it may make more sense to wait until closer to the holiday season.
-
With COVID-19 case rates rising in Florida, vaccine levels remain low. Experts say our relationship with the virus has changed. And that’s leaving them concerned.
-
A study finds that PTSD nearly doubled among college students, from 3.4% to 7.5%, from 2017 to 2022. The researchers called the increase "shocking."
-
COVID-19 cases are once again recording a summer spike with some of the highest weekly case reports seen this year. But what is our relationship with COVID four years after the pandemic outbreak?
-
The data Monday showed 2,972 reported deaths related to COVID-19, up from 2,740 in early June.
-
Advisers ultimately said sticking with JN.1 rather than its offshoots promises to offer a better chance at cross-protection. The FDA will decide the final recipe soon.